Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2020 | MDS, inflammation and AML

Yishai Ofran • 5 Mar 2020
MDS 2020
Acute Myeloid Leukemia Myelodysplastic Syndromes

Yishai Ofran, MD, Rambam Health Care Campus, Haifa, Israel, discusses the approach needed to treat patients with acute myeloid leukemia (AML) that has emerged post myelodysplastic syndromes (MDS). This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.

More from Yishai Ofran

1:21
Future treatment priorities for high-risk MDS
Yishai Ofran • 5 Mar 2020

Related Videos

2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals